NR4A1 and breast cancer: Targeted therapies for hormone receptor expression positive and for human epidermal growth factor receptor 2 (HER2, also known as ERBB2 or EGFR2) overexpression-positive disease have improved breast cancer mortality; however, breast cancer lacking these receptors, termed triple negative breast cancer (TNBC), presents particular challenges because of its highly aggressive nature.